Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma

BACKGROUND: The phase 3 LIBERTY ASTHMA QUEST study (ClinicalTrials.gov: NCT02414854) in patients with uncontrolled, moderate-to-severe asthma has demonstrated the efficacy and safety of dupilumab 200 and 300 mg every 2 weeks versus placebo. This post hoc analysis assessed the effect of dupilumab on...

Descripción completa

Detalles Bibliográficos
Autores principales: Corren, Jonathan, Katelaris, Constance H., Castro, Mario, Maspero, Jorge F., Ford, Linda B., Halpin, David M.G., Rice, Megan S., Radwan, Amr, Deniz, Yamo, Rowe, Paul J., Teper, Ariel, Djandji, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551561/
https://www.ncbi.nlm.nih.gov/pubmed/34266940
http://dx.doi.org/10.1183/13993003.04498-2020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551561/
https://www.ncbi.nlm.nih.gov/pubmed/34266940
http://dx.doi.org/10.1183/13993003.04498-2020

Ejemplares similares